DGAP-News: CVR Medical, Canon Showcasing Carotid Stenotic Scan (CSS) at PLASTEC West 2018
08.02.2018 (www.4investors.de) -
DGAP-News: CVR Medical Corp. / Key word(s): Miscellaneous
CVR Medical, Canon Showcasing Carotid Stenotic Scan (CSS) at PLASTEC West 2018
08.02.2018 / 14:30
The issuer is solely responsible for the content of this announcement.
Vancouver, British Columbia--(Newsfile Corp. - February 8, 2018) - CVR Medical Corp. (TSXV: CVM) (FSE: B3BN) (OTCQB: CRRVF) ('CVR Medical' or 'CVR') has joined Canon Virginia, Inc. (CVI) at PLASTEC West (February 6 - 8, 2018), the largest domestic conference and expo for advanced design and manufacturing of plastics technologies. CVI, subsidiary of Canon U.S.A., Inc, is the sole manufacturer of the cart for CVR Medical's 'Carotid Stenotic Scan (CSS)' device.CVI is sharing a booth with CVR at the event, highlighting abilities that allow for the unique, customized manufacturing of the CSS, as well as logistics and product support needs. The partnership, announced in 2017, established the production pathway through which the CSS will be launched later this year. PLASTEC West draws over 20,000 engineers, executives, and industry luminaries, providing invaluable brand exposure for both companies that are presenting ground-breaking solutions in manufacturing and medicine. Cannot view this image? Visit:http://orders.newsfilecorp.com/files/1933/32683_cvrcart.jpgCannot view this image? Visit:http://orders.newsfilecorp.com/files/1933/32683_cvrboothnewresize.jpgCVR COO Tony Robinson states, 'We are excited to attend [PLASTEC West] and show off the results from what has been an incredible partnership. Working with CVI to create the best possible design, and have it manufactured with a streamlined supply chain, has made it possible for us to aim for our highest goals. They have set a new industry quality standard, and we're proud to reflect that with our device.'For additional information on the organization, leadership, and current news, please visit the company's website www.CVRMed.com.About CVR MedicalCVR Medical is a company that is involved in an equal parts joint venture with CVR Global Inc. (the 'Joint Venture'). The Joint Venture operates in the medical industry focused on the commercialization of a proprietary subsonic, infrasonic, and low frequency sound wave analysis technology and has patents to a diagnostic device designed to detect and measure carotid arterial stenosis. CVR Medical is managed by a proven technical team. CVR Medical trades on the TSX Venture Exchange under the symbol CVM.ON BEHALF OF THE BOARD:(signed) 'Peter Bakema'CEO, President & DirectorFor further information contact:Peter Bakema, CEO, President and DirectorTelephone: (734) 718-5115Email: email@example.comBrisco Capital Partners Corp.Scott Koyich, PresidentTelephone: (403) 262-9888This press release contains forward-looking information that involves various risks and uncertainties regarding future events related to the Joint Venture. Such statements are subject to risks and uncertainties that may cause actual results, performance or developments to differ materially from those contained in the statements and are not guarantees of future performance of the Company. No assurance can be given that any of the events anticipated by the forward-looking statements will occur or, if they do occur, what benefits the Company will obtain from them. These forward-looking statements reflect management's current views and are based on certain expectations, estimates and assumptions which may prove to be incorrect. A number of risks and uncertainties could cause our actual results to differ materially from those expressed or implied by the forward-looking statements, including: (1) a downturn in general economic conditions in North America and internationally, (2) the inherent uncertainties and speculative nature associated with commercialization of technology and the practice of medicine, (3) a change in health regulations, (4) any number of events or causes which may delay or cease commercialization and development of the Joint Venture, (5) the risk that the Company or the Joint Venture does not execute its business plan, (6) inability to retain key employees, (7) inability to finance operations and growth, and (8) other factors beyond the Company's control. These forward-looking statements are made as of the date of this news release and, except as required by law, the Company assumes no obligation to update these forward-looking statements, or to update the reasons why actual results differed from those projected in the forward-looking statements. THE TSX VENTURE EXCHANGE INC. HAS NEITHER APPROVED NOR DISAPPROVED THE CONTENTS OF THIS PRESS RELEASE. NEITHER THE TSX VENTURE EXCHANGE NOR ITS REGULATION SERVICES PROVIDER (AS THAT TERM IS DEFINED IN THE POLICIES OF THE TSX VENTURE EXCHANGE) ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.
Click on, or paste the following link into your web browser, to view
the associated documents
08.02.2018 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.de
CVR Medical Corp.
End of News
DGAP News Service
Probiodrug: Drei entscheidende Jahre im Kampf gegen Alzheimer
Gigaset: „Werden bald eine ganz neue Art von Kommunikation erleben“